291.49
price down icon0.27%   -0.78
after-market After Hours: 289.00 -2.49 -0.85%
loading
Insulet Corporation stock is traded at $291.49, with a volume of 373.31K. It is down -0.27% in the last 24 hours and down -6.90% over the past month. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$292.27
Open:
$292.61
24h Volume:
373.31K
Relative Volume:
0.47
Market Cap:
$20.51B
Revenue:
$2.20B
Net Income/Loss:
$402.20M
P/E Ratio:
52.43
EPS:
5.56
Net Cash Flow:
$280.80M
1W Performance:
+2.07%
1M Performance:
-6.90%
6M Performance:
+5.19%
1Y Performance:
+51.95%
1-Day Range:
Value
$289.85
$293.00
1-Week Range:
Value
$284.00
$294.11
52-Week Range:
Value
$173.00
$329.33

Insulet Corporation Stock (PODD) Company Profile

Name
Name
Insulet Corporation
Name
Phone
978-600-7000
Name
Address
100 NAGOG PARK, ACTON, MA
Name
Employee
3,900
Name
Twitter
@insulet_uk
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PODD's Discussions on Twitter

Compare PODD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
PODD
Insulet Corporation
291.49 20.57B 2.20B 402.20M 280.80M 5.56
Medical Devices icon
ABT
Abbott Laboratories
128.01 219.83B 43.11B 13.98B 6.66B 7.98
Medical Devices icon
BSX
Boston Scientific Corp
106.47 156.58B 18.49B 2.51B 2.72B 1.68
Medical Devices icon
SYK
Stryker Corp
400.57 153.13B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
92.44 117.84B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
80.47 46.04B 5.69B 4.15B 623.10M 6.95

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-16-25 Initiated Truist Buy
May-30-25 Initiated Goldman Buy
May-13-25 Upgrade Wolfe Research Peer Perform → Outperform
Apr-29-25 Downgrade Wolfe Research Outperform → Peer Perform
Mar-06-25 Initiated RBC Capital Mkts Outperform
Nov-06-24 Initiated Bernstein Outperform
May-30-24 Initiated Redburn Atlantic Buy
May-07-24 Upgrade Wolfe Research Peer Perform → Outperform
Dec-21-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-04-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-02-23 Upgrade Jefferies Hold → Buy
Aug-21-23 Upgrade Citigroup Neutral → Buy
Aug-21-23 Downgrade Robert W. Baird Outperform → Neutral
May-30-23 Resumed Morgan Stanley Equal-Weight
Jan-26-23 Initiated Wolfe Research Peer Perform
Nov-04-22 Upgrade Piper Sandler Neutral → Overweight
Oct-18-22 Initiated Barclays Equal Weight
Oct-12-22 Initiated Jefferies Hold
Jul-11-22 Downgrade Citigroup Buy → Neutral
Mar-02-22 Resumed BofA Securities Buy
Feb-03-22 Upgrade BTIG Research Neutral → Buy
Feb-02-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade Oppenheimer Perform → Outperform
Jul-21-21 Resumed Cowen Outperform
May-25-21 Initiated Barclays Overweight
Apr-01-21 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-19-21 Upgrade Canaccord Genuity Hold → Buy
Jan-29-21 Downgrade Piper Sandler Overweight → Neutral
Dec-16-20 Downgrade Citigroup Buy → Neutral
Jul-28-20 Initiated Wells Fargo Overweight
Apr-24-20 Downgrade SVB Leerink Outperform → Mkt Perform
Apr-03-20 Initiated BofA/Merrill Neutral
Mar-31-20 Downgrade Berenberg Buy → Hold
Mar-05-20 Initiated Citigroup Buy
Dec-10-19 Initiated CFRA Sell
Oct-23-19 Initiated Stifel Hold
Oct-18-19 Downgrade Canaccord Genuity Buy → Hold
Oct-14-19 Downgrade BTIG Research Buy → Neutral
Oct-04-19 Downgrade UBS Buy → Neutral
Oct-03-19 Downgrade Guggenheim Buy → Neutral
Aug-06-19 Upgrade JP Morgan Neutral → Overweight
Jun-10-19 Downgrade Northland Capital Outperform → Market Perform
May-06-19 Upgrade BTIG Research Neutral → Buy
Apr-20-18 Initiated Berenberg Buy
Feb-22-18 Reiterated Barclays Overweight
Jan-08-18 Upgrade Raymond James Mkt Perform → Outperform
Nov-03-17 Upgrade Canaccord Genuity Hold → Buy
Sep-15-17 Initiated Barclays Overweight
View All

Insulet Corporation Stock (PODD) Latest News

pulisher
Jul 28, 2025

Why Insulet Corporation stock attracts strong analyst attentionFundamental + Technical Hybrid Stock Tips Shared - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive Insulet Corporation stock higher in 2025Low Risk Alerts Backed By Experts - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Insulet Corporation Sees Spike in Bullish Option FlowTechnical Stock Breakout Predictions Signal Entry Points - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

How does Insulet Corporation compare to its industry peersPost Market Guidance With High Returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What institutional investors are buying Insulet Corporation stockExceptional stock performance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Insulet CorporationTrack top-performing stocks in real-time - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the technical indicators suggesting about Insulet CorporationFree Real-Time Stock Data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Insulet Corporation stock attracting strong analyst attentionUnstoppable profit momentum - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is the dividend policy of Insulet Corporation stockUnlock the power of real-time market data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

What analysts say about Insulet Corporation stockFree Wealth Planning Blueprint - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What to Expect From Insulet's Q2 2025 Earnings Report - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Is Insulet Corporation stock overhyped or has real potentialTremendous gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Insulet Corporation a good long term investmentRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Insulet Corporation stock nowExplosive portfolio gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Insulet Corporation Q2 2025 Earnings Preview: Anticipating Significant GrowthNews and Statistics - IndexBox

Jul 24, 2025
pulisher
Jul 24, 2025

What To Expect From Insulet's Q2 2025 Earnings Report - Barchart.com

Jul 24, 2025
pulisher
Jul 24, 2025

Tubeless Insulin Pumps Market Attracts Startups Amid Booming - openPR.com

Jul 24, 2025
pulisher
Jul 24, 2025

Insulin Pumps Market Outlook Report 2025, with Leading - GlobeNewswire

Jul 24, 2025
pulisher
Jul 23, 2025

EOFlow’s 'EOPatch' Sales Banned in Europe - Businesskorea

Jul 23, 2025
pulisher
Jul 23, 2025

Insulet granted EU-wide injunction against EOFlow in default decision by UPC - MLex

Jul 23, 2025
pulisher
Jul 23, 2025

Insulin Pumps Market Outlook Report 2025, with Leading Player Profiles for Medtronic, Insulet, Tandem Diabetes Care, and More - Yahoo.co

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Insulet Corporation stock priceTriple-digit wealth increases - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Insulet Corporation Stock Analysis and ForecastFree Wealth Management Insights - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Digital Diabetes Management Market is projected to reach US$ - openPR.com

Jul 21, 2025

Insulet Corporation Stock (PODD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices STE
$228.37
price up icon 0.81%
medical_devices PHG
$28.02
price up icon 9.20%
$89.35
price down icon 0.20%
$77.72
price down icon 0.03%
medical_devices EW
$80.47
price up icon 2.52%
Cap:     |  Volume (24h):